ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Increase in serotypes 4 and 14 in invasive pneumococcal disease in adults aged 18 to 59 years. A retrospective population-based descriptive study during the period 2007-2025 in the Community of Madrid, Spain.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVaccination programmes against invasive pneumococcal disease (IPD) for adults aged 18-59 years in the Community of Madrid (CM) are targeted exclusively at people with risk factors. The aim of the study is to describe the epidemiology of IPD in adults aged 18 to 59 years between 2007 and 2025, evaluating serotype distribution temporal changes and its implications for PCVs use in the CM.
methodsA retrospective population-based descriptive study was conducted on clinical, epidemiological, vaccination status and microbiological information of IPD cases reported through the Notifiable Disease Surveillance System of the CM between 2007 and 2025. Incidence rates (IRs) and IR ratios (IRRs) were calculated overall, by vaccine and serotypes, using 2015-2019 as the reference period.
resultsOverall, 3,632 cases of IPD were reported in the population aged 18-59 years, 2,253 (62.0%) in males. Among them, 1,951 (53.7%) cases presented risk factors that made them eligible for vaccination. Vaccination was more frequent in patients with risk factors (16.7%) versus those without (3.2%). During the 2023-2025 period, IRs were below 6 cases/100,000 population. The most prevalent serotypes were 8 (24.9%), 3 (16.3%), 4 (9.4%), and 14 (6.9%). Compared to the 2015-2019 period, we observed increases in three PCV13-included serotypes in 2025: 14 (IRR: 6.7; 95% CI: 3.5 to 12.6), 9V (IRR: 6.2; 95% CI: 2.1 to 17.8), and 4 (IRR: 4.5; 95% CI: 2.5 to 7.8). Serotypes 14 and 9V were associated with penicillin non-susceptibility (PNS).
conclusionsPersistence of serotypes 8 and 3 and the notable increase in PCV20-covered serotypes 4 and 14 reinforce the importance of IPD close surveillance while PCV20 remains part of the adult immunisation schedule in the CM. The potential benefits of PCV21 in preventing disease caused by additional serotypes should also be considered.
Indexed as
Identifiers
42587238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.